Sign in →

Test ID TRCHM ToRCH Profile IgM, Serum

Useful For

Aids in the diagnosis of both congenital and acute acquired toxoplasmosis, cytomegalovirus, and herpes simplex virus

Profile Information

Test ID Reporting Name Available Separately Always Performed
TOXMP Toxoplasma Ab, IgM, S Yes Yes
CMVM Cytomegalovirus Ab, IgM, S Yes Yes
HSMR HSV Ab, IgM, S by IFA No Yes

Method Name

TOXMP: Enzyme-Linked Fluorescence Assay (ELFA)

CMVM: Multiplex Flow Immunoassay (MFI)

HSMR: Immunofluorescence Assay (IFA)

Reporting Name

Torch Profile IgM, S

Specimen Type

Serum

Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Specimen Volume: 1 mL

Specimen Minimum Volume

0.9 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 14 days
  Frozen  14 days

Clinical Information

Toxoplasma gondii:

Toxoplasma gondii is an obligate intracellular protozoan parasite that is capable of infecting a variety of intermediate hosts including humans. Infected definitive hosts (cats) shed oocysts in feces that rapidly mature in the soil and become infectious.(1) Toxoplasmosis is acquired by humans through ingestion of food or water contaminated with cat feces or through eating undercooked meat containing viable oocysts. Vertical transmission of the parasite through the placenta can also occur, leading to congenital toxoplasmosis. Following primary infection, Toxoplasma gondii can remain latent for the life of the host; the risk for reactivation is highest among immunosuppressed individuals.

 

Seroprevalence studies performed in the United States indicate that approximately 9% to 11% of individuals between the ages of 6 and 49 have antibodies to Toxoplasma gondii.(2) Infection of immunocompetent adults is typically asymptomatic. In symptomatic cases, patients most commonly present with lymphadenopathy and other nonspecific constitutional symptoms, making definitive diagnosis difficult to determine.

 

Severe-to-fatal infections can occur among patients with AIDS or individuals who are otherwise immunosuppressed. These infections are thought to be caused by reactivation of latent infections and commonly involved the central nervous system.(3)

 

Transplacental transmission of the parasites resulting in congenital toxoplasmosis can occur during the acute phase of acquired maternal infection. The risk of fetal infection is a function of the time at which acute maternal infection occurs during gestation.(4) The incidence of congenital toxoplasmosis increases as pregnancy progresses; conversely, the severity of congenital toxoplasmosis is greatest when maternal infection is acquired early during pregnancy. A majority of infants infected in utero are asymptomatic at birth, particularly if maternal infection occurs during the third trimester, with sequelae appearing later in life. Congenital toxoplasmosis results in severe generalized or neurologic disease in about 20% to 30% of the infants infected in utero; approximately 10% exhibit ocular involvement only and the remainder are asymptomatic at birth. Subclinical infection may result in premature delivery and subsequent neurologic, intellectual, and audiologic defects.

 

Cytomegalovirus (CMV):

CMV is a member of the Herpesviridae family of viruses and usually causes asymptomatic infection after which it remains latent in patients, primarily within bone marrow derived cells.(5) Primary CMV infection in immunocompetent individuals may also manifest as a mononucleosis-type syndrome, similar to primary Epstein-Barr virus infection, with fever, malaise, and lymphadenopathy.

 

CMV is a significant cause of morbidity and mortality among bone marrow or solid organ transplant recipients, individuals with AIDS, and other immunosuppressed patients due to virus reactivation or from a newly acquired infection.(6,7) Infection in these patient populations can affect almost any organ and lead to multi-organ failure. CMV is also responsible for congenital disease among newborns and is 1 of the ToRCH infections (toxoplasmosis, other infections including syphilis, rubella, CMV, and herpes simplex virus: HSV).

 

CMV seroprevalence increases with age. In the United States, the prevalence of CMV-specific antibodies increases from approximately 36% to over 91% in adolescents between the ages of 6 through 11 and adults over 80 years old, respectively.(8)

 

Herpes Simplex Virus (HSV):

HSV types 1 and 2 are members of the Herpesviridae family of viruses and produce infections that may range from mild stomatitis to disseminated and fatal disease. Clinical conditions associated with HSV infection include gingivostomatitis, keratitis, encephalitis, vesicular skin eruptions, aseptic meningitis, neonatal herpes, genital tract infections, and disseminated primary infection.

 

Infections with HSV types 1 and 2 can differ significantly in their clinical manifestations and severity. HSV type 2 primarily causes urogenital infections and is found almost exclusively in adults. HSV type 1 is closely associated with orolabial infection, although genital infection with this virus can be common in certain populations.

 

The diagnosis of HSV infections are routinely made based on clinical findings and supported by laboratory testing using PCR or viral culture. However, in instances of subclinical or unrecognized HSV infection, serologic testing for IgG-class antibodies to type-specific HSV glycoprotein G (gG) may be useful. There are several circumstances in which it may be important to distinguish between infection caused by HSV types 1 and 2.(9) For example, the risk for reactivation is highest for HSV type 2 and the method of antiviral therapy may differ depending on the specific type of HSV-causing disease. In addition, the results of HSV type-specific IgG testing is sometimes used during pregnancy to identify risks of congenital HSV disease and allow for focused counseling prior to delivery.(10,11)

Reference Values

Toxoplasma Ab, IgM

Negative

 

Toxoplasma IgM Value

<0.55 (negative)

0.55-<0.65 (equivocal)

≥0.65 (positive)

 

CYTOMEGALOVIRUS, IgM

Negative (reported as positive, negative, or equivocal)

 

HERPES SIMPLEX VIRUS, IGM

Negative (reported as positive or negative)

Cautions

Results must be used in conjunction with clinical symptoms and patient history.


Positive test results may not be valid in persons who have received blood transfusions or other blood products in the past several months.

 

Toxoplasma:

Negative results do not preclude recent primary Toxoplasma gondii infection. A negative result could indicate either no previous exposure or also could be seen in cases of remote exposure with subsequent loss of detectable antibody. A second specimen drawn at a later point in time may be needed to rule out a recent infection.

 

Positive serologic results alone are not diagnostic of Toxoplasma gondii infection. For example, infections with Epstein-Barr virus (EBV) have been suspected to elicit antigen-specific IgM responses (eg, false-positive IgM Toxoplasma reactions) in individuals previously sensitized to a variety of non-EBV infectious agents.

 

Since persisting IgM levels may be detected long after the onset of acquired infection, the use of a single serological test result must be used with caution in those cases when it is critical to establish the time of infection. This applies to the diagnosis of acute Toxoplasma gondii infection acquired during pregnancy. Determination of the date of infection based solely on the results of detectable IgM antibody to Toxoplasma gondii is not recommended. That determination should include clinical history and previous serology, since low levels of IgM antibody may persist for a year or more. The use of a test to determine a rise in IgG antibody to Toxoplasma gondii (TOXGP / Toxoplasma gondii Antibody, IgG, Serum or TOXOP / Toxoplasma gondii Antibody, IgM and IgG (Separate Determinations), Serum) may provide additional information as to the date of infection. Therefore, the FDA has instructed commercial suppliers of Toxoplasma IgM kits to recommend Toxoplasma IgG testing also be performed.

 

Cytomegalovirus (CMV):

Sera drawn very early during the acute stage of infection may have undetectable levels of CMV IgM.

 

Immunocompromised patients may have impaired immune responses, and nonreactive IgM results may be due to delayed seroconversion and do not rule-out current infection.

 

CMV IgM results should not be used alone to diagnose CMV infection. Results should be considered in conjunction with clinical presentation, patient history, and other laboratory findings. In cases of suspected disease, submit a second specimen for testing in 10 to 14 days.

 

The performance characteristics of these assays have not been evaluated in immunosuppressed or organ transplant recipients and have not been established for cord blood or for testing of neonates. These assays should not be used for screening blood or plasma donors.

 

Immune complexes or other immunoglobulin aggregates present in patient specimens may cause increased nonspecific binding and produce false-positive results.

 

Potential cross-reactivity for CMV IgM may occur with specimens positive for EBV viral capsid antigen IgM and parvovirus B19 IgM.

 

Herpes Simplex Virus (HSV):

Individuals infected with HSV may not exhibit detectable levels of IgM antibody in the early stages of infection. This assay does not discriminate between antibodies to HSV-1 and HSV-2.

Day(s) Performed

Monday through Saturday; 9 a.m.

Report Available

Same day/1 day

Performing Laboratory

Mayo Medical Laboratories in Rochester

CPT Code Information

86645-CMV IgM

86694-HSV IgM

86778-Toxoplasma IgM

NY State Approved

Yes